Compare Charles River Laboratories Intl. Inc (CRL) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Kinross Gold Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while Kinross Gold Corporation trades at $23.72 (market cap $28.24B). The key difference: Kinross Gold Corporation is far larger — about 2.5× Charles River Laboratories Intl. Inc's market cap, and Kinross Gold Corporation pays a 0.61% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | KGC | |
|---|---|---|
Market Cap | $11.14B | $28.24B |
Sector | Health | Basic Materials |
52-Week High | $233.60 | $38.06 |
52-Week Low | $145.57 | $15.33 |
Enterprise Value | $14.00B | $26.80B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
KGC trades at $23.48, down 2.73% on the day, amid a bearish technical signal. Fundamentally, the company shows robust health with revenue growth from $3.5B in 2022 to $7.05B in 2025 and a net income margin of 35.99%. Recent quarters have consistently beaten EPS estimates. Analyst consensus is bullish with a $37.20 price target, though technical indicators suggest near-term pressure.
The outlook for KGC is positive based on strong fundamentals and growth trajectory, but investors face near-term technical headwinds and sensitivity to gold prices. The stock presents a value opportunity with a low P/E of 9.99, though execution on production guidance and cost management remain key to realizing upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
